Biotechnology company Circio Holding is set to collaborate with The University of Texas Medical Branch (UTMB) to evaluate treatments for infectious diseases. The partnership aims to design and test Circio’s circVEC technology for the prevention and treatment of infections, cancer and gene therapy. The technology allows for the long-term expression of proteins, protecting against dangerous viral pathogens. “Our unique circVec technology modifies the core […]
To read this content in full, you need to login.
Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!